Synutra International, Inc., a leading infant formula company in China and a producer, marketer and seller of nutritional products for infants, children and adults, today reported financial results for the Company’s third quarter and nine months ended December 31, 2009. [More]

Cynosure, Inc., a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced financial results for the three and 12 months ended December 31, 2009. [More]

Nu Skin Enterprises, Inc. today announced that its board of directors declared a 9 percent increase in the quarterly cash dividend to $0.125 per share. Annually, this would increase the dividend to $0.50, up from $0.46 in the prior year. The increase begins in the first quarter and will be paid on March 17, 2010, to shareholders of record on Feb. 26, 2010. [More]

Delcath Systems, Inc. (DCTH), a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today the signing of its first research, distribution, sales and marketing agreement for its Percutaneous Hepatic Perfusion (PHP) System (the Delcath PHP System™). The agreement grants Chi-Fu Trading Co., Ltd. the exclusive right to market and sell the Delcath PHP System in Taiwan for hepatic malignancies and infectious disease upon Taiwan Food and Drug Administration (TFDA) approval, and any other approved use, with a conditional option for Singapore. [More]

Hoya Corporation today announced financial results for the third quarter ended December 31, 2009. Net sales were 106.8 billion yen for the quarter, a 5.2% decrease from 112.7 billion yen in the same period last year. Operating income was 18.9 billion yen, a 13.8% increase from 16.6 billion yen in the same period last year, mainly due to increase in orders and productivity. Compared to the second quarter ended September 30, 2009, sustained recovery in orders since April resulted in an increase of both net sales and operating income. [More]

LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus® brand, today announced financial and operating results for the three and 12 month periods ended December 31, 2009. [More]

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results. [More]

Compugen Ltd. today reported financial results for the fourth quarter and year ending December 31, 2009. [More]

Triple-S Management Corporation, the largest managed care company in Puerto Rico, today announced consolidated revenues of $516.9 million and operating income of $34.2 million for the three months ended December 31, 2009. [More]

Clinical Data, Inc. (NASDAQ: CLDA) today announced the Company’s operational and financial results for its third fiscal quarter ended December 31, 2009, confirming its plans to submit a new drug application (NDA) for vilazodone for the treatment of depression this quarter. [More]

Targeted Genetics Corporation (the “Company”) today announced that it has completed the technology transfer portion of the September 2009 asset sale transaction executed between the Company and Genzyme Corporation (“Genzyme”) and has received the full $7.0 million provided for in the asset purchase agreement. [More]

Coventry Health Care, Inc. today reported consolidated operating results for the quarter ended December 31, 2009. Operating revenues totaled $3.4 billion for the quarter with net earnings of $109.1 million, or $0.74 earnings per diluted share (EPS). For the year ended December 31, 2009, total revenues from continuing operations were $13.9 billion with net earnings from continuing operations of $315.3 million, or $2.14 per diluted share. [More]

Centene Corporation today announced its financial results for the quarter and year ended December 31, 2009. The results of operations for our New Jersey health plan, University Health Plans, are classified as discontinued operations. [More]

Sanofi-aventis announced today that it has successfully completed its tender offer for all outstanding shares of common stock of Chattem, Inc.. [More]

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan. [More]